Sign in Subscribe
Diseases

Personalized Dose Reduction Strategies for Treating Axial Spondyloarthritis Show Promising Results

Strategic Insights

— 1 min read

Research conducted at Bach Mai Hospital has revealed that personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs (bDMARDs) may offer a feasible approach to maintaining clinical efficacy while reducing costs for patients with axial spondyloarthritis (AS). The study, published in BMC Rheumatology, aimed to evaluate the clinical effectiveness and cost-efficiency of bDMARD dose reduction in patients with AS and apply machine learning to identify key factors influencing disease control.

Key Takeaways:

  • The study included 368 AS patients who received 3 months of full-dose bDMARDs, with 215 initial responders achieving clinical remission according to the Assessment of SpondyloArthritis international Society (ASAS) 40 criteria.
  • BDMARD dose reduction was associated with preserved clinical outcomes and lower costs, suggesting it may be a viable strategy for selected patients under close clinical supervision.
  • Predictive modeling provided actionable insights to optimize personalized treatment strategies, balancing efficacy and economic sustainability.
  • The findings support further evaluation of dose reduction strategies, especially in resource-limited settings, to inform potential integration into routine practice.
  • The study highlights the importance of personalized medicine in managing AS, where patients may benefit from tailored treatment approaches.
  • Researchers suggest that dose reduction strategies may be particularly beneficial in resource-limited settings, where access to bDMARDs can be limited.
  • The study's predictive modeling approach can help identify key factors influencing disease control and inform treatment decisions.

Statistics:

  • 368 AS patients were included in the study.
  • 215 (58%) patients achieved clinical remission according to the ASAS 40 criteria.
  • BDMARD dose reduction was associated with preserved clinical outcomes and lower costs.
  • The cost savings associated with dose reduction were estimated to be around $1-2 per patient per year.
  • The study involved a 12-month prospective design, with patients receiving 3 months of full-dose bDMARDs followed by a 9-month dose reduction period.

Sources:

  • Personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs for treating axial spondyloarthritis: a clinical and economic evaluation with predictive modeling. BMC Rheumatology, 2025, 9(1):1-13. (BMC Rheumatology - https://bmcrheumatol.biomedcentral.com/).
  • Health & Medicine Week. June 20, 2025; p 4308.
  • NewsRx. Researchers from Bach Mai Hospital Detail Findings in Personalized Medicine (Personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs for treating axial spondyloarthritis: a clinical and economic evaluation with ...). Health & Medicine Week. June 20, 2025; p 4308.

Read more